Advertisement

Depression pp 163-182 | Cite as

Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs)

  • Siegfried Kasper
  • Gereon Höflich
  • Hans-Peter Scholl
  • Hans-Jürgen Möller
Conference paper

Zusammenfassung

Selektive Serotoninwiederaufnahmehemmer (SSRIs) stellen eine neue Klasse von Antidepressiva dar, die in den letzten 10 Jahren Eingang in die Psychiatrie gefunden haben. Diese Substanzen wurden mit dem Ziel entwickelt, im Vergleich zu trizyklischen oder tetrazyklischen Antidepressiva weniger Nebenwirkungen bzw. Komplikationen hervorzurufen. Darüber hinaus wurde für Subgruppen depressiver Erkrankungen, z.B. gehemmte bzw. somatisierte Depressionen, eine spezifische Wirksamkeit angestrebt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amin MM, Anath JV, Colemans BS et al. (1984) Fluvoxamine, antidepressant effect confirmed in a placebo controlled international study. Clin Neuropharmacol 7 (Suppl 1): 312–319Google Scholar
  2. Beasley CM, Dornseif BE, Bosomworth JC et al. (1991) Fluoxetine and suicide a meta-analysis of controlled trials of treatment for depression. Br Med J 303: 685–692CrossRefGoogle Scholar
  3. Bech P (1988) A review of the antidepressant properties of serotonin reuptake inhibitors. In: Gastpar M, Wakelin JS (eds) Selective 5-HT reuptake inhibitors. Novel or Commonplace agents? Karger, Basel, pp 58–69Google Scholar
  4. Bulusu I, Alderson M (1984) Suicides 1950–1982. Office of population censuses and Survey HMSO. Population Trends 35: 11–13Google Scholar
  5. Cassano GB, Conti L, Massimetti G et al. (1986) Use of a standardized documentation system ( BLIPS/BPD) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine and placebo. Psychopharmacol Bull 22: 52–58PubMedGoogle Scholar
  6. Coleman BS, Block BA (1982) Fluvoxamine-maleate. A serotonergic antidepressant: A comparison with chlorimipramine. Neurol Psychopharmacol Biol Psychiatr 6: 475–478CrossRefGoogle Scholar
  7. Danish University Antidepressant Group (1986) Citalopram, clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacol 90: 131–299Google Scholar
  8. Danish University Antidepressant Group (1990) Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern than clomipramine in a controlled multicentre study. J Affective Disord 18: 284–299Google Scholar
  9. Dominguez RA, Goldstein BJ, Jacobson AG, Steinbook RM (1985) A doubleblind placebo-controlled study for fluvoxamine and imipramine in depression. J Clin Psychiatry 46: 84–87PubMedGoogle Scholar
  10. Feighner J, Boyer WF, Meredith C, Hendrickson GG (1989) A placebo-controlled inpatients comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 4: 239–244PubMedCrossRefGoogle Scholar
  11. Fuger J, Zinner HJ, Kasper S, Möller HJ (1992) Efficacy of the new generation antidepressants - a statistical metaanalysis. Pharmacopsychiatry, in pressGoogle Scholar
  12. Ginestet D et al. (1989) Etude de la fluocetine dans le traitement des depressions endogènes et des mélancolies. Int Clin Psychopharmacol (Suppl 1 ): 37–40Google Scholar
  13. Goodman-Gilman et al. (1990) The pharmacological basis of therapeutics, VIII Ed. Pergamon, New York, p 412Google Scholar
  14. Guelfi JD, Dreyfus JF, Pichot P (1983) The GEP. A double-blind controlled clinical trial of comparing fluvoxamine with imipramine. Br J Clin Pharmacol 15 (Suppl 3): 411–417Google Scholar
  15. Guze SB, Robins E (1970) Suicide among primary affective disorders. Br J Psychiatry 117: 437–438PubMedCrossRefGoogle Scholar
  16. Hagnell O, Lanke J, Rorsman B (1981) Suicide rates in the Lundbystudy; mental illness as a risk factor for suicide. Neuropsychology 7: 248–253Google Scholar
  17. Henry JA (1989) A fatal toxicity index for antidepressant poisoning. Acta Psychiatr Scand 80: 37–45CrossRefGoogle Scholar
  18. Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST (1983) A doubleblind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 15 (Suppl 3): 433–438Google Scholar
  19. Jonghe de F, Swinkels JA (1992) The safety of antidepressants. Drugs 43 (Suppl 2): 40–47PubMedCrossRefGoogle Scholar
  20. Kasper S, Voll G, Vieira A, Kick H (1990) Response to total sleep deprivation before and during treatment with fluvoxamine of maprotiline in patients with major depression - results of a double-blind study. Pharmacopsychiatry 23: 135–142PubMedCrossRefGoogle Scholar
  21. Kasper S, Fuger J, Möller HJ (1992a) Comparative efficacy of antidepressants. Drugs 43 (Suppl 2): 11–23PubMedCrossRefGoogle Scholar
  22. Kasper S, Dötsch M, Vieira A, Möller HJ (1992b) Plasma levels of fluvoxamine and maprotiline and clinical response in major depression. Eur Neurpsychopharmacol 3: 13–21CrossRefGoogle Scholar
  23. Laakman G, Blaschke D, Engel R, Schwarz A (1988) Fluoxetine vs amitriptyline in the treatment of depressed outpatients. Br J Psychiatry 153 (Suppl 3): 64–68Google Scholar
  24. Lapierre YD, Browne M, Horn E et al. (1987) Treatment of major effective disorder with fluvoxamine. J Clin Psychiatry 48: 65–68PubMedGoogle Scholar
  25. Mendlewicz J (1992) Efficacy of fluvoxamine in severe depression. Drugs 43 (Suppl 2): 32–39PubMedCrossRefGoogle Scholar
  26. Milne RJ, Goa KL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 450–477PubMedCrossRefGoogle Scholar
  27. Möller HJ, Berzewski H, Gonzales N et al. (1991) A double-blind, multicenter study of paroxetine and amitriptyline in depressed outpatients. Presented at the 5th World Congress of Biological Psychiatry. Florence, June, 9–14Google Scholar
  28. Möller HJ, Fuger J, Kasper S (1993) Statische Metaanalyse der Wirksamkeit neuerer Antidepressiva. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuropsychopharmaka, Bd 3. Springer, Wien New York (im Druck)Google Scholar
  29. Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery D (1981) A doubleblind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand (Suppl 290 ) 63: 314–327CrossRefGoogle Scholar
  30. Montgomery SA, Pinder RM (1987) Do some antidepressants promote suicide? Psychopharmacology 92: 265–266PubMedCrossRefGoogle Scholar
  31. Montgomery SA, Lambert MT, Lynch SPJ (1988) The risk of suicide with antidepressants. Int Clin Psychopharmacol 3 (Suppl 2): 15–24PubMedGoogle Scholar
  32. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatr Scand 78: 384–390PubMedCrossRefGoogle Scholar
  33. Norton KRW, Sierling LI, Bhat AV, Rao B, Paykel ES (1984) A doubleblind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affective Disord 7: 297–308CrossRefGoogle Scholar
  34. Ottevanger E (1991) The efficacy of fluvoxamine in patients with severe depression. Br J Clin Res 2: 125–132Google Scholar
  35. van Praag HM, Kahn R, Asnis GM et al. (1987) Therapeutic indications for serotonin potentiating compounds: a hypotheses. Biol Psychiatry 22: 205–212PubMedCrossRefGoogle Scholar
  36. Potter WZ, Karoum F, Linnoila M (1984) Common mechanism of action of biochemically „specific” antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 8: 153–161PubMedCrossRefGoogle Scholar
  37. Reimher FW, Byerley WF, Ward MF, Lebegue BJ, Wender PH (1988) Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 24: 200–205Google Scholar
  38. Rickeis K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51: 9–12Google Scholar
  39. Rouillon F, Phillips R, Serrurier E, Ansart E, Gerard MJ (1989) Prophylactic efficacy of maprotiline on relapses of unipolar depression. Encephale 15: 527–534PubMedGoogle Scholar
  40. Starkey IR, Lawson AAH (1980) Psychiatric aspect of acute poisoning with tricyclic and related antidepressants. A ten year review. Scott Med J 25: 303–308PubMedGoogle Scholar
  41. Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207–210PubMedGoogle Scholar
  42. Wagner W, Piekkenpol B, Gray TE, Viaskamp H, Essers H (1992) Review of fluvoxamine safety database. Drugs 43 (Suppl 2): 48–52PubMedCrossRefGoogle Scholar
  43. Wakelin J (1988) The role of serotonin in depression and suicide. Adv Biol Psychiatry 17: 70–83Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Siegfried Kasper
  • Gereon Höflich
  • Hans-Peter Scholl
  • Hans-Jürgen Möller

There are no affiliations available

Personalised recommendations